🩸
Our haematological malignancy research covers leukaemias, lymphomas, and myelomas, with a focus on precision medicine and novel CAR-T cell therapies.
Learn MoreDeveloping in-house CAR-T manufacturing protocols that reduce treatment costs from $400,000 to under $30,000 per patient.
Flow cytometry and next-generation sequencing–based MRD detection to guide treatment de-escalation in acute leukaemias.
Characterizing the mutational landscape of diffuse large B-cell lymphoma in Indian patients to identify prognostic biomarkers.
NCT06234504
RecruitingPI: Dr. T. Rajkumar
NCT06234505
ActivePI: Dr. R. Swaminathan
Donations support our pioneering CAR-T cell therapy program and help make life-saving treatments accessible to every patient regardless of economic status.
Donate Now
.png&w=96&q=75){kind=small}